reviewed april 2026|next review october 2026|88 physicians psi has verified|353 published studies
Melanotan I (Afamelanotide)
Melanotan I (afamelanotide) is a linear 13-amino-acid alpha-MSH analog FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic condition causing extreme photosensitivity, delivered as a subcutaneous implant providing 60-day sustained release.
Evidence landscape: 353 published studies
353 published items. 36 human studies and 112 animal studies. The most clinically validated melanocortin agonist with FDA approval and post-marketing data.
- 36 Human
- 112 Animal
- 52 Reviews
- 153 Other research
FDA-approved as Scenesse for EPP. Also approved by the EMA. The highest level of regulatory validation on this platform.
Preferential MC1R agonism drives eumelanin production without the sexual function or appetite effects of non-selective Melanotan II.
Subcutaneous implant provides 60-day sustained release. This controlled delivery is different from injectable peptide formulations.
PSI Assessment
For people living with erythropoietic protoporphyria - a rare genetic condition where sunlight exposure causes severe phototoxic reactions - afamelanotide represents a validated treatment backed by Phase III trial data and FDA approval. Melanotan I is the selective melanocortin agonist, and that selectivity is what separates it from Melanotan II. Where Melanotan II activates receptors involved in sexual function, appetite, and melanogenesis simultaneously, afamelanotide targets MC1R preferentially, driving protective pigment production without the multi-system side effect profile. Here is what the clinical evidence shows.
FDA-approved as Scenesse for EPP. Selective MC1R agonism without the sexual function or appetite effects of Melanotan II. Phase III data with post-marketing surveillance.
The mechanism is preferential MC1R (melanocortin 1 receptor) agonism, driving eumelanin (photoprotective brown-black pigment) production in melanocytes without significant activation of MC3R, MC4R, or MC5R. This selectivity is the key pharmacological difference from Melanotan II. In EPP, the increased eumelanin provides a photoprotective layer that allows patients to tolerate sunlight exposure without the severe phototoxic reactions that define their condition. The subcutaneous implant formulation provides 60-day sustained release.
What the evidence supports
FDA-approved as Scenesse for EPP based on Phase III trial data. Selective MC1R agonism drives eumelanin production without the sexual function, appetite, or mole-change concerns associated with non-selective Melanotan II. Post-marketing surveillance provides ongoing safety data. 36 human studies represent the deepest clinical evidence base of any melanocortin agonist.
What is not yet established
Efficacy for cosmetic tanning or photoprotection outside the EPP indication. Whether vitiligo applications will advance to registration. Long-term effects of sustained melanogenesis stimulation in non-EPP populations. Comparison with topical melanogenesis approaches.
Research Evidence
The findings below cover the Phase III EPP approval, the selective MC1R mechanism, and photoprotection research beyond EPP.
Evidence by condition
Evidence dimensions across Melanotan I's approved and investigated uses. EPP has the deepest evidence with FDA approval. Vitiligo and photoprotection have supporting data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| EPP | ||||
| Photoprotection | ||||
| Vitiligo |
Phase III clinical trials demonstrated significantly increased duration of sun exposure without pain in EPP patients. The subcutaneous implant provides sustained MC1R activation and eumelanin production over approximately 60 days.
EPP is a rare genetic condition affecting approximately 1 in 75,000 to 200,000 people. The FDA approval is based on meaningful clinical benefit for this population.
Selective MC1R agonism produces eumelanin without significant activation of MC3R (appetite), MC4R (sexual function), or MC5R. This pharmacological selectivity is the key distinction from Melanotan II.
The selective derivative (PT-141) exists specifically because Melanotan II's non-selective profile makes it unsuitable for targeted therapeutic use. Melanotan I's selectivity enables a cleaner therapeutic profile.
Combination of afamelanotide implant with narrowband UVB (ultraviolet B) phototherapy produced faster and more extensive repigmentation than phototherapy alone in vitiligo studies.
Vitiligo research is the most active non-EPP investigation. Whether this will advance to regulatory submission is not yet determined.
36 Human|112 Animal|52 Reviews
View all 353 indexed studiesHow Melanotan I (Afamelanotide) Works
Melanotan I (afamelanotide) is a linear 13-amino-acid synthetic analog of alpha-MSH with preferential activity at the MC1R receptor on melanocytes.
Melanotan I specifically activates the MC1R receptor on skin cells, telling them to produce more melanin (pigment). This provides a protective tan that shields EPP patients from the light sensitivity that makes sun exposure extremely painful. Because it targets MC1R more selectively, it does not produce the sexual arousal or appetite effects seen with Melanotan II.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Afamelanotide selectively activates MC1R receptors on melanocytes, stimulating eumelanin production through the cAMP signaling cascade involving protein kinase A (PKA), CREB transcription factor, and MITF (microphthalmia-associated transcription factor). Eumelanin provides UV photoprotection by absorbing radiation before it reaches photosensitive substrates. The selective MC1R targeting avoids the sexual function, appetite, and cardiovascular effects seen with non-selective melanocortin agonists like Melanotan II.
What is Melanotan I (Afamelanotide) being studied for?
Researchers are studying Melanotan I (Afamelanotide) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Melanotan I (Afamelanotide) overall. This means a compound can have human studies for one condition but only animal data for another.
EPP
·FDA ApprovedFDA-approved as Scenesse for erythropoietic protoporphyria. Administered as a subcutaneous implant every 2 months. Phase III trials demonstrated significantly increased pain-free time in sunlight.
Limitations: Approved only for EPP. High cost due to designation as a treatment for a rare disease. Implant-based delivery limits flexibility.
Photoprotection
·Animal StudiesStudies in fair-skinned individuals showed increased melanin density and reduced UV-induced DNA damage. The eumelanin increase provides genuine photoprotection.
Limitations: Not approved for general photoprotection or cosmetic tanning. Whether broad-population use is justified is debated.
Vitiligo
·Animal StudiesCombination of afamelanotide with narrowband UVB produced faster and more extensive repigmentation than phototherapy alone in clinical studies.
Limitations: Not FDA-approved for vitiligo. Studies are small. Whether the benefit justifies the cost is unclear.
Safety and Regulatory Status
FDA Status: FDA-approved as Scenesse for erythropoietic protoporphyria. EMA-approved.
Prescription status: Available by prescription for the approved indication. Delivered as a subcutaneous implant providing 60-day sustained release.
Safety context: Long-term controlled trial data and post-marketing surveillance available. Common side effects include implant site reactions, nausea, and skin darkening (expected therapeutic effect). Mole monitoring recommended.
FDA-approved with characterized safety from clinical trials and post-marketing surveillance. The selective MC1R profile is more favorable than non-selective Melanotan II.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Melanotan I (Afamelanotide) discussion.
Comparison and Related Research
Melanotan I is most often compared with Melanotan II (non-selective, significant safety concerns) and PT-141 (MC4R-focused derivative).
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The pivotal Phase III randomized, double-blind, placebo-controlled trial that led to European approval of afamelanotide (a melanotan I analog, marketed as Scenesse) for erythropoietic protoporphyria (EPP). Patients receiving subcutaneous afamelanotide implants experienced significantly more time in sunlight without pain and a greater increase in melanin density compared to placebo, demonstrating clinically meaningful photoprotection.Langendonk JG et al., 2015 in N Engl J Med. View on PubMed
- 2.A Phase II study evaluating afamelanotide in EPP patients demonstrated increased pain-free sun exposure and elevated melanin density following subcutaneous implant treatment. Patients reported meaningful improvements in quality of life during the treatment period, with the ability to spend more time outdoors without experiencing the severe phototoxic reactions characteristic of EPP.Harms JH et al., 2009 in Photochem Photobiol. View on PubMed
- 3.A controlled study in fair-skinned volunteers demonstrated that subcutaneous afamelanotide significantly increased melanin density and eumelanin content in the skin. When subjects were subsequently exposed to UV radiation, those who had received afamelanotide showed less UV-induced DNA damage (fewer thymine dimers) compared to placebo, suggesting the induced pigmentation provided genuine photoprotective benefit beyond cosmetic tanning.Barnetson RS et al., 2006 in J Invest Dermatol. View on PubMed
- 4.A post-marketing review of afamelanotide's clinical use in EPP, covering real-world evidence accumulated after European approval. The review confirmed sustained efficacy in increasing pain-free light exposure and an acceptable safety profile over extended treatment periods, while noting that the drug's availability remained limited to specialized treatment centers.Wensink D et al., 2021 in Expert Rev Clin Pharmacol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.